Clarivate has completed the sale of its Life Sciences & Healthcare segment to Altaris for $600 million, streamlining its business to focus on Academia & Government and Intellectual Property segments. This strategic move aims to sharpen Clarivate's portfolio, enhance financial flexibility by reducing debt, and support growth through AI-driven innovation. The company will update its 2026 financial guidance following the divestiture and plans to invest in innovation and customer support with a stronger balance sheet. Clarivate's future focus will be on providing trusted data and AI-powered solutions to research institutions and intellectual property markets.
Clarivate's recent strategic sale of its Life Sciences & Healthcare segment provides context for market activity. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 07, 2026 03:03 WIB: out of 150 priced US stocks, 93 rose and 56 fell. Notable movers include Seagate Technology Holdings PLC (STX) at USD 806.00 with a 9.14% decline, Freshworks Inc (FRSH) at USD 13.79 rising 7.90%, and Nebius Group NV (NBIS) at USD 250.28 up 7.61%.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
